Total Payments
$23,429
2024 Payments
$3,228
Companies
43
Transactions
685
Medicare Patients
2,032
Medicare Billing
$221,951
Payment Breakdown by Category
Food & Beverage$12,110 (51.7%)
Research$8,126 (34.7%)
Travel$2,903 (12.4%)
Gifts$259.92 (1.1%)
Education$28.83 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,110 | 664 | 51.7% |
| Unspecified | $8,126 | 5 | 34.7% |
| Travel and Lodging | $2,903 | 6 | 12.4% |
| Gift | $259.92 | 7 | 1.1% |
| Education | $28.83 | 3 | 0.1% |
Payments by Type
General
$15,302
680 transactions
Research
$8,126
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $6,838 | 54 | $0 (2024) |
| ABBVIE INC. | $3,177 | 193 | $0 (2024) |
| PFIZER INC. | $2,093 | 30 | $0 (2024) |
| Genentech USA, Inc. | $2,087 | 4 | $0 (2024) |
| Eli Lilly and Company | $1,876 | 4 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,123 | 71 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $889.28 | 56 | $0 (2024) |
| Janssen Biotech, Inc. | $648.88 | 39 | $0 (2024) |
| Braintree Laboratories, Inc. | $610.89 | 36 | $0 (2022) |
| Ferring Pharmaceuticals Inc. | $569.63 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,228 | 68 | Genentech USA, Inc. ($2,087) |
| 2023 | $1,529 | 72 | ABBVIE INC. ($478.03) |
| 2022 | $1,639 | 106 | ABBVIE INC. ($426.92) |
| 2021 | $8,611 | 146 | Celgene Corporation ($6,404) |
| 2020 | $1,773 | 67 | Eli Lilly and Company ($756.45) |
| 2019 | $1,642 | 81 | AbbVie, Inc. ($411.02) |
| 2018 | $2,176 | 66 | Eli Lilly and Company ($723.94) |
| 2017 | $2,830 | 79 | PFIZER INC. ($1,695) |
All Payment Transactions
685 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: Immunology | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.83 | General |
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $2.43 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: LIVER DISEASE | ||||||
| 10/22/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Rare Disease | ||||||
| 10/18/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $289.40 | General |
| 10/17/2024 | Genentech USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $772.50 | General |
| 10/17/2024 | Genentech USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $764.14 | General |
| 10/17/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $261.18 | General |
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/16/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Genetic Disease | ||||||
| 10/03/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $2.22 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/12/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $22.12 | General |
| Category: THERAPY FOR CSID | ||||||
| 09/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Immunology | ||||||
| 08/26/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multi-Center, Multi-National, Randomized, Double | Celgene Corporation | $6,250 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $1,146 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $730.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 415 | 419 | $316,900 | $46,700 |
| 2022 | 12 | 400 | 413 | $340,700 | $45,129 |
| 2021 | 13 | 643 | 660 | $512,500 | $72,801 |
| 2020 | 11 | 574 | 608 | $369,750 | $57,320 |
Total Patients
2,032
Total Services
2,100
Medicare Billing
$221,951
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 162 | 162 | $161,200 | $21,758 | 13.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 53 | $15,975 | $4,881 | 30.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 28 | 28 | $31,550 | $4,825 | 15.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 40 | 40 | $15,000 | $2,670 | 17.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $7,875 | $2,562 | 32.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 14 | 14 | $14,000 | $2,342 | 16.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 39 | 39 | $31,200 | $2,223 | 7.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 29 | $8,700 | $1,973 | 22.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $17,000 | $1,903 | 11.2% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 16 | 16 | $14,400 | $1,565 | 10.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 152 | 152 | $182,400 | $19,891 | 10.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 53 | $15,900 | $5,010 | 31.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 19 | 19 | $26,600 | $2,944 | 11.1% |
| 45382 | Control of bleeding of upper large bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $18,200 | $2,598 | 14.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 49 | 49 | $39,200 | $2,373 | 6.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 35 | $9,900 | $2,285 | 23.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $6,300 | $2,040 | 32.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $5,200 | $2,017 | 38.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $13,000 | $1,745 | 13.4% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 17 | 17 | $15,300 | $1,707 | 11.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 16 | 16 | $5,700 | $1,317 | 23.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 15 | $3,000 | $1,203 | 40.1% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 210 | 210 | $252,500 | $28,714 | 11.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 73 | 73 | $21,900 | $9,413 | 43.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 58 | 66 | $19,800 | $6,123 | 30.9% |
About Dr. Satinder Gill, MD
Dr. Satinder Gill, MD is a Gastroenterology healthcare provider based in Lansdowne, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487614913.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Satinder Gill, MD has received a total of $23,429 in payments from pharmaceutical and medical device companies, with $3,228 received in 2024. These payments were reported across 685 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($12,110).
As a Medicare-enrolled provider, Gill has provided services to 2,032 Medicare beneficiaries, totaling 2,100 services with total Medicare billing of $221,951. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Lansdowne, VA
- Active Since 03/27/2006
- Last Updated 02/05/2026
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1487614913
Products in Payments
- HUMIRA (Biological) $808.22
- STELARA (Biological) $710.01
- XIFAXAN (Drug) $637.35
- Humira (Biological) $588.67
- ZEPOSIA (Drug) $587.61
- RINVOQ (Biological) $502.03
- ZENPEP (Drug) $459.25
- TRULANCE (Drug) $422.45
- ENTYVIO (Biological) $396.45
- XELJANZ (Drug) $383.13
- LINZESS (Drug) $373.60
- CREON (Drug) $362.24
- CIMZIA (Drug) $351.27
- SUPREP BOWEL PREP (Drug) $308.84
- GATTEX (Drug) $280.18
- Sucraid (Drug) $218.23
- Linzess (Drug) $184.84
- Trulance (Drug) $176.26
- SKYRIZI (Biological) $175.49
- DUPIXENT (Biological) $174.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Lansdowne
Dr. Hani Sabahi, M.d, M.D
Gastroenterology — Payments: $17,357
Gastroenterology $17,357
Dr. Rahul Kataria, M.d, M.D
Gastroenterology — Payments: $8,532
Gastroenterology $8,532
Sanjeev Wasan, Md, MD
Gastroenterology — Payments: $7,365
Gastroenterology $7,365
Hiwot Desta, Md, MD
Gastroenterology — Payments: $4,812
Gastroenterology $4,812
Juan De La Ossa, Do, DO
Gastroenterology — Payments: $999.84
Gastroenterology $999.84